Ruiyuan Cao

TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.

TL;DR: Evaluated the antiviral effect of HCQ against SARS-CoV-2 infection in comparison to CQ in vitro and concluded that CQ appears to be the drug of choice for large-scale use due to its availability, proven safety record, and a relatively low cost.

TL;DR: Six currently available and licensed anti-influenza drugs against SARS-CoV-2 are evaluated and it is suggested that arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate of COVID-19 patients.

TL;DR: Evaluated anti-SARS-CoV-2 activities of nine artemisinin-related compounds in vitro and carried out a time-of-drug-addition assay to explore their antiviral mode of action; a pharmacokinetic prediction model was established to predict the therapeutic potential of selected compounds against COVID-19 and revealed lumefantrine showed therapeutic promise due to high plasma and lung drug concentrations after multiple dosing.

TL;DR: Nitazoxanides and its bioactive metabolite, tizoxanide, have anti-ZIKV potential in vitro, and it is identified that they exerts antiviral effect possibly by targeting the viral postattachment step.